Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company whose news flow centers on the development of gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases. Company press releases and SEC-referenced communications highlight regular updates on clinical trial progress, preclinical data presentations, and corporate developments.
Investors following IN8bio news can expect detailed coverage of its key programs, including INB-100 for leukemias in the post-transplant setting and DeltEx™ Drug-Resistant Immunotherapy (DRI) γδ T cells in INB-200 and INB-400 trials for newly diagnosed glioblastoma. Recent announcements describe extended median progression-free survival in GBM patients receiving repeated doses of DeltEx DRI γδ T cells, favorable safety profiles without dose-limiting toxicities, and multi-center data presented at major scientific meetings such as the American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO).
News items also cover IN8bio’s γδ T cell engager pipeline, including INB-619, a CD19-targeted, pan-γδ T cell engager. The company has reported preclinical data from lupus and systemic lupus erythematosus (SLE) donor models, showing complete B cell depletion with minimal inflammatory cytokine release, and has presented these findings at conferences such as the American College of Rheumatology (ACR) Convergence Meeting and the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
In addition, IN8bio issues news releases on its proprietary manufacturing platform, scientific awards, financial results and financing transactions. Readers of INAB news can use this page to monitor clinical milestones, data readouts, scientific conference presentations and material corporate events that the company discloses through press releases and related filings.
IN8bio announced significant survival benefits from concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) in high-grade glioma models. The findings, published in Scientific Reports, support the clinical development of the company’s Drug Resistant Immunotherapy (DRI) technology. Currently, a Phase 1 trial is evaluating DRI with TMZ in glioblastoma multiforme at the University of Alabama at Birmingham. This approach aims to enhance tumor response while maintaining immune functionality.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at BioFuture 2021 on October 5 at 10:30 a.m. EDT and participate in a panel on oncology at 1:30 p.m. EDT. Additionally, Kate Rochlin, VP of Operations, will present on gamma-delta T-cell programs at the Advanced Therapies Congress & Expo 2021 the same day at 11:30 a.m. EDT. IN8bio focuses on innovative therapies for tumors using its DeltEx platform, with two Phase 1 trials ongoing for gamma-delta T-cell products targeting glioblastoma and leukemia.
IN8bio, Inc. announced operational and financial highlights for Q2 2021, reporting significant progress in its Phase 1 clinical trials for INB-200 and INB-100. The successful completion of the first cohort treatment in both trials demonstrates strong potential in solid tumors and leukemia. Following a $40M IPO in August 2021, the company bolstered its cash position to $32.6M. However, IN8bio recorded a net loss of $3.1M for the quarter, with R&D expenses rising to $2.1M, indicating ongoing investment in its clinical programs.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at two virtual events: NewYorkBIO Virtual Breakfast Series on August 31 at 9 am EDT, and H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-14. The presentations will highlight the company's innovative gamma-delta T-cell therapies using its DeltEx platform. The H.C. Wainwright presentation will be available for 90 days post-release. IN8bio is currently conducting Phase 1 clinical trials for its lead product candidates targeting glioblastoma and leukemia.
IN8bio has completed dosing for the first cohort in a Phase 1 clinical trial of INB-100, a gamma-delta T-cell therapy for leukemia patients undergoing haploidentical stem cell transplant. No severe adverse infusion reactions or dose limiting toxicities were reported among the three patients. The first two patients remain in complete remission over one year post-dosing. The trial aims to evaluate safety, tolerability, and overall survival, with topline data expected in 2023. IN8bio focuses on innovative T-cell therapies to improve treatment outcomes for leukemia and other cancers.
IN8bio (Nasdaq: INAB) has appointed Emily Fairbairn and Luba Greenwood to its Board of Directors. Both appointees bring extensive experience in the biopharmaceutical and life sciences sectors. Fairbairn, an influential investor and former CEO of Ascend Capital, focuses on corporate governance, while Greenwood's background includes leadership roles at Google Life Sciences and Roche. Their terms will end at the 2022 annual stockholders' meeting. IN8bio aims to advance its clinical-stage gamma-delta T-cell therapies for cancer treatment, utilizing its innovative DeltEx platform.
IN8bio, Inc. (Nasdaq: INAB) has announced the pricing of its initial public offering (IPO) at $10 per share, totaling gross proceeds of $40 million before expenses. The offering consists of 4,000,000 shares and is expected to close on August 3, 2021. Additionally, an underwriter option allows for 600,000 more shares to be purchased. IN8bio specializes in gamma-delta T cell therapies for cancer treatment and is currently conducting Phase 1 trials for its lead candidates targeting glioblastoma and leukemia.